Clinical effect of cypofol and etomidate combined with propofol in the treatment of digestive endoscopy in elderly patients

Phase 4

Completed

• Conditions: None

• Registration Number: ChiCTR2400088889
• Lead Sponsor: Chongqing General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

? Choose a painless gastroscopy or gastroenteroscopy, and sign an informed consent<br>?Age =65 years and =90 years, BMI=28kg/m2<br>? ASA I~III grade;<br>? Duration of treatment =1h

Exclusion Criteria

? ASA grade III unstable state after treatment<br> ?Have a history of serious cardiovascular disease (such as heart failure, severe arrhythmia, moderate and severe stenosis or regurgitation of heart valves); Family history of Adams-Stokes syndrome; Patients with unstable angina pectoris, or myocardial infarction within the last 6 months; QTcF interval =450ms(corrected by Fridericia's formula); A history of tachycardia/bradycardia and/or resting electrocardiography requiring medical treatment heart rate <50 beats/min, or second degree type II, third degree atrioventricular block<br>?A history of hypertension with systolic blood pressure >180mmHg and/or diastolic blood pressure > 100mmHg after treatment with antihypertensive drugs; Systolic blood pressure <90mmHg and/or diastolic blood pressure <60mmHg; Heart rate <50 or >100 beats/min<br>? Craniocerebral injury, possible history of intracranial hypertension, brain aneurysm, cerebrovascular accident; A history of mental illness (schizophrenia, mania, psychosis) or long-term psychotropic medications, and cognitive impairment<br>? Respiratory insufficiency, acute stage of obstructive emphysema, active stage of asthma, upper respiratory tract infection in the past week (accompanied by fever, nasal congestion, sore throat, cough and other symptoms)<br>? Severe abnormal liver and kidney function (severe abnormal liver function: ALT, bound bilirubin, AST, ALP, one of total bilirubin > 2 times the upper limit of normal; Severe renal dysfunction: Cr clearance<30ml/min), Scr > 443µmol/L; Patients with severe portal hypertension or increased intra-abdominal pressure<br>?History of severe diabetic complications (diabetic ketoacidosis, hyperosmolar coma, various infections, large vascular diseases, diabetic nephropathy)<br>? Severe infection, trauma or major surgery within 4 weeks<br>? Severe anemia Hb < 70g/L<br>? Patients at high risk of reflux aspiration;<br>?Definite history of sleep apnea syndrome and difficult airway;<br>? Allergy to narcotic drugs<br>? Participated in another drug clinical study within the past 30 days

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of patients with successful sedation;

Secondary Outcome Measures

Name	Time	Method
incidence of hypotension;incidence of hypoxemia;apnea;duration of sedation onset;recovery time;discharge criteria;injectiong pain;sleep quality;cognitive memory function;nausea. vomiting.myoclnus;